Premium
The use of adalimumab for cricoarytenoid arthritis in ankylosing spondylitis—an effective therapy
Author(s) -
Desuter Gauthier,
Duprez Thierry,
Huart Caroline,
Gardiner Quentin,
Verbruggen Gust
Publication year - 2011
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.21343
Subject(s) - ankylosing spondylitis , medicine , blockade , adalimumab , spondyloarthropathy , magnetic resonance imaging , etanercept , arthritis , cartilage , radiology , tumor necrosis factor alpha , surgery , anatomy , receptor
This report describes cartilaginous regeneration in a cricoarytenoid joint affected by spondyloarthropathy using tumor necrosis factor‐alpha (TNF‐α) blockade, monitored by magnetic resonance (MR) and computed tomography (CT) imaging. This case is interesting for several reasons. It is only the eighth case of destructive ankylosing spondylitis‐related cricoarytenoid arthritis published in the English language literature. It describes, for the first time, full recovery of vocal cord mobility following TNF‐α blockade. It is also the first case to be published with MR imaging demonstrating regeneration of the cricoarytenoid cartilage following treatment. This case represents a landmark in the treatment of patients presenting with destructive arthritis involving the cricoarytenoid joint.